Lessons Learned From Awake ECMO Approach in Covid-19-Related Acute Respiratory Distress Syndrome-a Scoping Review

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F71009396%3A_____%2F25%3AN0000007" target="_blank" >RIV/71009396:_____/25:N0000007 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61988987:17110/25:A2603D89

Výsledek na webu

<a href="https://www.tandfonline.com/doi/epdf/10.2147/TCRM.S507120?src=getftr&utm_source=clarivate&getft_integrator=clarivate" target="_blank" >https://www.tandfonline.com/doi/epdf/10.2147/TCRM.S507120?src=getftr&utm_source=clarivate&getft_integrator=clarivate</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2147/TCRM.S507120" target="_blank" >10.2147/TCRM.S507120</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Lessons Learned From Awake ECMO Approach in Covid-19-Related Acute Respiratory Distress Syndrome-a Scoping Review

Popis výsledku v původním jazyce

During the COVID-19 pandemic, specific COVID-19-related conditions renewed interest in the full-awake venovenous extracorporeal membrane oxygenation (faV–V ECMO) approach, in which ECMO is applied to awake, cooperative, and non-intubated patients. This scoping review aims to provide a descriptive overview offa V–V ECMO in patients with COVID-19-related acute respiratory distress syndrome (CARDS). We searched the PubMed, Web of Science, and Scopus databases using the keywords “awake ECMO” or “spontaneous breathing AND ECMO”, combined with “COVID-19”, “SARS-CoV-2” or “coronavirus”, utilizing the Boolean operator “AND”. The search included papers published from November 1, 2019, to December 31, 2024. Sixty-four papers were assessed for eligibility at the abstract level, and fourteen articles (seven small-sample cohort studies and seven case reports) comprising 95 patients were included in the final analysis. The most frequent reasons for preferringfaV-V ECMO over mechanical ventilation were barotrauma and patient refusal of intubation and mechanical ventilation. Thefa V-V ECMO strategy was successful (ie, patients not intubated, disconnected from ECMO, and discharged from the hospital) in 36.4% of cases (cohort studies only). The incidence of defined severe adverse events (bleeding, thrombosis, cannula malposition, delirium, and progression of barotrauma) was considered low. The mortality rate for CARDS patients treated withfaV-V ECMO (including only patients from cohort studies) reached 33.0%, notably lower than the 48% reported for CARDS patients treated with V-V ECMO in the ELSO registry. Patients who were intubated due to worsening respiratory failure duringfaV-V ECMO had significantly higher mortality. Infectious complications, sepsis, and multiorgan failure were the most frequent causes of death. However, significant heterogeneity in the definitions and reporting of management, ECMO-related complications, and outcomes was observed across the papers. Despite the heterogeneity of the data,fa V-V ECMO in CARDS patients can be considered a safe approach associated with a lower mortality rate than that reported in the overall V-V ECMO CARDS population. © 2025 Sklienka et al.

Název v anglickém jazyce

Lessons Learned From Awake ECMO Approach in Covid-19-Related Acute Respiratory Distress Syndrome-a Scoping Review

Popis výsledku anglicky

During the COVID-19 pandemic, specific COVID-19-related conditions renewed interest in the full-awake venovenous extracorporeal membrane oxygenation (faV–V ECMO) approach, in which ECMO is applied to awake, cooperative, and non-intubated patients. This scoping review aims to provide a descriptive overview offa V–V ECMO in patients with COVID-19-related acute respiratory distress syndrome (CARDS). We searched the PubMed, Web of Science, and Scopus databases using the keywords “awake ECMO” or “spontaneous breathing AND ECMO”, combined with “COVID-19”, “SARS-CoV-2” or “coronavirus”, utilizing the Boolean operator “AND”. The search included papers published from November 1, 2019, to December 31, 2024. Sixty-four papers were assessed for eligibility at the abstract level, and fourteen articles (seven small-sample cohort studies and seven case reports) comprising 95 patients were included in the final analysis. The most frequent reasons for preferringfaV-V ECMO over mechanical ventilation were barotrauma and patient refusal of intubation and mechanical ventilation. Thefa V-V ECMO strategy was successful (ie, patients not intubated, disconnected from ECMO, and discharged from the hospital) in 36.4% of cases (cohort studies only). The incidence of defined severe adverse events (bleeding, thrombosis, cannula malposition, delirium, and progression of barotrauma) was considered low. The mortality rate for CARDS patients treated withfaV-V ECMO (including only patients from cohort studies) reached 33.0%, notably lower than the 48% reported for CARDS patients treated with V-V ECMO in the ELSO registry. Patients who were intubated due to worsening respiratory failure duringfaV-V ECMO had significantly higher mortality. Infectious complications, sepsis, and multiorgan failure were the most frequent causes of death. However, significant heterogeneity in the definitions and reporting of management, ECMO-related complications, and outcomes was observed across the papers. Despite the heterogeneity of the data,fa V-V ECMO in CARDS patients can be considered a safe approach associated with a lower mortality rate than that reported in the overall V-V ECMO CARDS population. © 2025 Sklienka et al.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30203 - Respiratory systems

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Therapeutics and Clinical Risk Management

ISSN

1178-203X

e-ISSN

1178-203X

Svazek periodika

21

Číslo periodika v rámci svazku

-

Stát vydavatele periodika

NZ - Nový Zéland

Počet stran výsledku

14

Strana od-do

655-668

Kód UT WoS článku

001490311400001

EID výsledku v databázi Scopus

2-s2.0-105006743197